Swedish biotech AnaCardio raises $70.9M to advance 'safer' heart failure drug

Summary

Swedish biotech AnaCardio raised €62.5 million ($70.9 million) in Series B funding to advance its chronic advanced heart failure drug toward registrational development. The capital will extend the company's runway for clinical progression.